title: Characterization and molecular analysis of macrolide-resistant Mycoplasma pneumoniae clinical isolates obtained in Japan.
abstract: In recent years, Mycoplasma pneumoniae strains that are clinically resistant to macrolide antibiotics have occasionally been encountered in Japan. Of 76 strains of M. pneumoniae isolated in three different areas in Japan during 2000 to 2003, 13 strains were erythromycin (ERY) resistant. Of these 13 strains, 12 were highly ERY resistant (MIC, > or =256 microg/ml) and 1 was weakly resistant (MIC, 8 microg/ml). Nucleotide sequencing of domains II and V of 23S rRNA and ribosomal proteins L4 and L22, which are associated with ERY resistance, showed that 10 strains had an A-to-G transition at position 2063 (corresponding to 2058 in Escherichia coli numbering), 1 strain showed A-to-C transversion at position 2063, 1 strain showed an A-to-G transition at position 2064, and the weakly ERY-resistant strain showed C-to-G transversion at position 2617 (corresponding to 2611 in E. coli numbering) of domain V. Domain II and ribosomal proteins L4 and L22 were not involved in the ERY resistance of these clinical M. pneumoniae strains. In addition, by using our established restriction fragment length polymorphism technique to detect point mutations of PCR products for domain V of the 23S rRNA gene of M. pneumoniae, we found that 23 (24%) of 94 PCR-positive oral samples taken from children with respiratory infections showed A2063G mutation. These results suggest that ERY-resistant M. pneumoniae infection is not unusual in Japan.
authors.affiliation: Department of Bacterial Pathogenesis and Infection Control, National Institute of Infectious Diseases, Tokyo, Japan.
authors.forename: Mayumi
authors.initials: M
authors.lastname: Matsuoka
authors.forename: Mitsuo
authors.initials: M
authors.lastname: Narita
authors.forename: Norio
authors.initials: N
authors.lastname: Okazaki
authors.forename: Hitomi
authors.initials: H
authors.lastname: Ohya
authors.forename: Tsutomu
authors.initials: T
authors.lastname: Yamazaki
authors.forename: Kazunobu
authors.initials: K
authors.lastname: Ouchi
authors.forename: Isao
authors.initials: I
authors.lastname: Suzuki
authors.forename: Tomoaki
authors.initials: T
authors.lastname: Andoh
authors.forename: Tsuyoshi
authors.initials: T
authors.lastname: Kenri
authors.forename: Yuko
authors.initials: Y
authors.lastname: Sasaki
authors.forename: Atsuko
authors.initials: A
authors.lastname: Horino
authors.forename: Miharu
authors.initials: M
authors.lastname: Shintani
authors.forename: Yoshichika
authors.initials: Y
authors.lastname: Arakawa
authors.forename: Tsuguo
authors.initials: T
authors.lastname: Sasaki
mesh_terms: D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D001483:Base Sequence; D002648:Child; D002675:Child, Preschool; D024881:Drug Resistance, Bacterial; D004917:Erythromycin / Q000494:pharmacology; D005260:Female; D006801:Humans; D007564:Japan / Q000453:epidemiology; D018942:Macrolides / Q000494:pharmacology*; D008297:Male; D008826:Microbial Sensitivity Tests; D008969:Molecular Sequence Data; D009177:Mycoplasma pneumoniae / Q000187:drug effects* / Q000235:genetics*; D011019:Pneumonia, Mycoplasma / Q000382:microbiology*; D017354:Point Mutation; D012150:Polymorphism, Restriction Fragment Length; D012329:RNA, Bacterial / Q000235:genetics; D012338:RNA, Ribosomal, 23S / Q000235:genetics; D020133:Reverse Transcriptase Polymerase Chain Reaction; D012269:Ribosomal Proteins / Q000235:genetics / Q000378:metabolism
chemical_list: D000900:Anti-Bacterial Agents; D018942:Macrolides; D012329:RNA, Bacterial; D012338:RNA, Ribosomal, 23S; D012269:Ribosomal Proteins; D004917:Erythromycin